GSK plc files 6-K

Japan's Ministry of Health, Labour and Welfare has expanded the approval for GSK's RSV vaccine, Arexvy, to include adults aged 18-49 years at increased risk, making it the first RSV vaccine approved for this age group and all adults 60 and older in Japan. The prescribing information was also updated to explicitly include immunocompromised patients as an increased risk group.